3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Doxorubicin
4
pembrolizumab
3
Specimen Handling
3
toripalimab
2
abemaciclib
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
Ifosfamide
2
Biopsy
2
silmitasertib
1
selinexor
1
peposertib
1
pemigatinib
1
pazopanib
1
palbociclib
1
mirdametinib
1
liposomal doxorubicin
1
X-Rays
1
Vincristine
1
Trabectedin
1
Temozolomide
1
Surgical Procedures, Operative
1
Radiation
1
Quality of Life
1
Proton Therapy
1
Neoadjuvant Therapy
1
Irinotecan
1
Injections
1
Histamine H2 Antagonists
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Liposarcoma
×
Histamine H2 Antagonists
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled